The authors have generated important resources such as a reference dataset of early primate development by utilizing single-cell transcriptomic technology together with induced pluripotent stem cells ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th.The company reported ($0.40) earnings per share for the quarter, missing the ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...

Finally, UBS Group dropped their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th.

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

FuriosaAI, a South Korean startup that makes chips for AI applications, has rejected an $800 million acquisition offer from Meta, opting instead to focus on developing and producing its AI chips ...

Intel’s first chip fabrication plant in Ohio may not open until 2030 at the earliest. According to a report in The Columbus Dispatch, Intel has slowed the building of its promised $28 billion ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Amazon.com Inc.’s cloud unit has built its first quantum-computing chip, joining a growing roster of technology companies showing off futuristic hardware. Alphabet Inc.’s Google and Microsoft ...